Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas

Klibanski, 2009, Dopamine agonist therapy in prolactinomas: when can treatment be discontinued?, J Clin Endocrinol Metab, 94, 2247, 10.1210/jc.2009-0999 Oh, 2011, Dopamine agonist-resistant prolactinomas, J Neurosurg, 114, 1369, 10.3171/2010.11.JNS101369 Lopez, 2005, Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists, Fertil Steril, 84, 756, 10.1016/j.fertnstert.2005.05.006 Lamberts, 1982, Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas, Neuroendocrinology, 34, 339, 10.1159/000123324 Jiang, 2010, Analysis of differential gene expression by fiber-optic BeadArray and pathway in prolactinomas, Endocrine, 38, 360, 10.1007/s12020-010-9389-2 Miyakoshi, 2008, Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway, Endocr Pathol, 19, 261, 10.1007/s12022-008-9048-9 Elston, 2008, Wnt pathway inhibitors are strongly down-regulated in pituitary tumors, Endocrinology, 149, 1235, 10.1210/en.2007-0542 Giles, 2011, Wnt signalling in estrogen-induced lactotroph proliferation, J Cell Sci, 124, 540, 10.1242/jcs.078642 Jonsson, 2002, Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas, Cancer Res, 62, 409 Nelson, 2004, Convergence of Wnt,{beta}-catenin, and cadherin pathways, Science, 303, 1483, 10.1126/science.1094291 Polakis, 2000, Wnt signaling and cancer, Genes Dev, 14, 1837, 10.1101/gad.14.15.1837 Kouzmenko, 2004, Wnt/beta-catenin and estrogen signaling converge in vivo, J Biol Chem, 279, 40255, 10.1074/jbc.C400331200 Miyakoshi, 2009, The expression of Wnt4 is regulated by estrogen via an estrogen receptor alpha-dependent pathway in rat pituitary growth hormone-producing cells, Acta Histochem Cytochem, 42, 205, 10.1267/ahc.09033 Li, 2009, Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism, Neuro Endocrinol Lett, 30, 268 Lv, 2011, Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line, J Neurooncol, 102, 237, 10.1007/s11060-010-0326-2 Leng, 2011, Effects of an estrogen receptor antagonist on proliferation, prolactin secretion and growth factor expression in the MMQ pituitary prolactinoma cell line, J Clin Neurosci, 18, 1694, 10.1016/j.jocn.2011.06.013 DeLellis RA, Lloyd RV, Heitz PU, et al. Pathology and genetics of tumours of endocrine organs. WHO classification of tumours. The International Agency for Research on Cancer, Lyon, France 2004. Lundin, 1992, Volume of pituitary macroadenomas: assessment by MRI, J Comput Assist Tomogr, 16, 519, 10.1097/00004728-199207000-00004 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta] CT method, Methods, 25, 402, 10.1006/meth.2001.1262 Gueorguiev, 2009, Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis, Pituitary, 12, 245, 10.1007/s11102-008-0147-x Elston, 2010, Identification of Wnt family inhibitors: a pituitary tumor directed whole genome approach, Mol Cell Endocrinol, 326, 48, 10.1016/j.mce.2010.02.039 Evans, 2008, Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses, Pituitary, 11, 231, 10.1007/s11102-007-0082-2 Calle-Rodrigue, 1998, Prolactinomas in male and female patients: a comparative clinicopathologic study, Mayo Clin Proc, 73, 1046, 10.4065/73.11.1046 Delgrange, 1997, Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study, J Clin Endocrinol Metab, 82, 2102 Zarate, 2010, Estrogen receptors and signaling pathways in lactotropes and somatotropes, Neuroendocrinology, 92, 215, 10.1159/000321683 Lieberman, 1978, Estrogen control of prolactin synthesis in vitro, Proc Natl Acad Sci USA, 75, 5946, 10.1073/pnas.75.12.5946 Scully, 1997, Role of estrogen receptor-alpha in the anterior pituitary gland, Mol Endocrinol, 11, 674